NT5E and neoplasm: MEDI9447 (a monoclonal antibody specific for the ectoenzyme, CD73) can reduce immunosuppression via increasing CD8+ T cells, inhibiting myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment, finally inhibit tumor progress.